TY - JOUR
T1 - Effects of empagliflozin in women and men with acute myocardial infarction
T2 - An analysis from the EMMY trial
AU - the EMMY study group
AU - Sourij, Caren
AU - Aziz, Faisal
AU - Tripolt, Norbert J.
AU - Siller-Matula, Jolanta
AU - Pferschy, Peter N.
AU - Kolesnik, Ewald
AU - Wallner, Markus
AU - Eyileten, Ceren
AU - Postula, Marek
AU - Oulhaj, Abderrahim
AU - Sourij, Harald
AU - von Lewinski, Dirk
N1 - Publisher Copyright:
© 2023 Hellenic Society of Cardiology
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (Pinteraction = 0.984), left ventricular ejection fraction (Pinteraction = 0.812), left ventricular end systolic volume (Pinteraction = 0.183), or left ventricular end diastolic volume (Pinteraction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.
AB - Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (Pinteraction = 0.984), left ventricular ejection fraction (Pinteraction = 0.812), left ventricular end systolic volume (Pinteraction = 0.183), or left ventricular end diastolic volume (Pinteraction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.
KW - Acute Myocardial Infarction
KW - Cardiovascular Disease
KW - Empagliflozin
KW - SGLT2i
KW - Sex Differences
UR - http://www.scopus.com/inward/record.url?scp=85176783628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176783628&partnerID=8YFLogxK
U2 - 10.1016/j.hjc.2023.05.007
DO - 10.1016/j.hjc.2023.05.007
M3 - Article
C2 - 37236318
AN - SCOPUS:85176783628
SN - 1109-9666
VL - 75
SP - 3
EP - 8
JO - Hellenic Journal of Cardiology
JF - Hellenic Journal of Cardiology
ER -
